Lipocine Inc. LPCN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Lipocine Inc. (LPCN) is a healthcare company listed in the US with a market value of about $19M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of -$9M, a net margin of -249.2%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -31%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 92% below the current price.
About Lipocine
Lipocine is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $428031 in 2018 to $2M in 2025, growth of about 24.4% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 434% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $2M | $11M | -$3M | $500000 | $16M | $0 | $164990 | $428031 | $0 | $0 |
| Net income | -$9M | -$10M | $8352 | -$16M | -$11M | -$634399 | -$21M | -$13M | -$12M | -$21M | -$19M |
| Free cash flow | — | — | -$1M | -$12M | -$12M | -$4M | — | — | -$12M | -$17M | -$18M |
| EPS (diluted) | $-1.28 | $-1.69 | $0.00 | $-3.14 | $-2.15 | $-0.17 | $-6.43 | $-8.45 | $-9.30 | $-17.75 | $-17.59 |
| Net margin | -249.2% | -487.1% | 0.1% | 573.6% | -2151.7% | -3.9% | — | -7883.7% | -2724.1% | — | — |
| ROIC | — | -56.6% | -5.1% | -69.5% | -26.9% | 5.2% | -67.9% | -75.8% | -45.4% | -88.3% | -58.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Lipocine stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 92% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Lipocine pay a dividend?
Not currently.
Is Lipocine a good stock to buy?
We do not give buy or sell advice. Lipocine scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.